Beijing Continent Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 574

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 2

Beijing Continent General Information

Description

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Contact Information

Website
www.bjcontinent.com
Formerly Known As
Beijing Continent Pharmaceuticals Company
Ownership Status
Acquired/Merged
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 507-509, Building B, Wangjing SOHO Tower
  • No. 1 Futong East Street, Chaoyang District
  • Beijing
  • China
+86 010
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Manufacturing, Life Sciences
Corporate Office
  • Room 507-509, Building B, Wangjing SOHO Tower
  • No. 1 Futong East Street, Chaoyang District
  • Beijing
  • China
+86 010

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Beijing Continent Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 30-Oct-2023 Completed Profitable
8. IPO 28-Feb-2022 Cancelled Profitable
7. Secondary Transaction - Private 17-Nov-2020 Completed Profitable
6. IPO Cancelled Profitable
5. Secondary Transaction - Private 23-Dec-2015 Completed Profitable
4. Secondary Transaction - Private 24-Feb-2014 Completed Profitable
3. Later Stage VC 23-Oct-2013 Completed Profitable
2. Merger/Acquisition 14-Oct-2011 $2.11M Completed Profitable
1. Secondary Transaction - Private 11-Apr-2006 $1.04M Completed Generating Revenue
To view Beijing Continent’s complete valuation and funding history, request access »

Beijing Continent Patents

  • 693

    Total Documents Applications and Grants

  • Total Patents Families

  • 218

    Granted

  • 33

    Pending

  • Expiring in next 12 mo

Beijing Continent Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4520344-A1 Dipeptide derivative composition, preparation method therefor, and use thereof Pending 06-May-2022
AU-2022275085-A1 Application of hydronidone in preparation of drug for treating or preventing chronic hepatitis b with liver fibrosis Pending 14-May-2021
US-20240261271-A1 Application of hydronidone in preparation of drug for treating or preventing chronic hepatitis b with liver fibrosis Pending 14-May-2021
EP-4353229-A4 Application of hydronidone in preparation of drug for treating or preventing chronic hepatitis b with liver fibrosis Pending 14-May-2021
CA-3222521-A1 Application of hydronidone in preparation of drug for treating or preventing chronic hepatitis b with liver fibrosis Pending 14-May-2021 A61K31/4412
To view Beijing Continent’s complete patent history, request access »

Beijing Continent Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Beijing Continent Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Beijing Continent Factory Corporation Minority
Gyre Therapeutics Corporation Majority
Lapam Capital Venture Capital Minority
To view Beijing Continent’s complete investors history, request access »

Ready to get started?

Request a free trial

Beijing Continent FAQs

  • When was Beijing Continent founded?

    Beijing Continent was founded in 2002.

  • Where is Beijing Continent headquartered?

    Beijing Continent is headquartered in Beijing, China.

  • What is the size of Beijing Continent?

    Beijing Continent has 574 total employees.

  • What industry is Beijing Continent in?

    Beijing Continent’s primary industry is Drug Discovery.

  • Is Beijing Continent a private or public company?

    Beijing Continent is a Private company.

  • What is Beijing Continent’s current revenue?

    The current revenue for Beijing Continent is .

  • How much funding has Beijing Continent raised over time?

    Beijing Continent has raised $1.64M.

  • Who are Beijing Continent’s investors?

    Beijing Continent Factory, Gyre Therapeutics, and Lapam Capital have invested in Beijing Continent.

  • When was Beijing Continent acquired?

    Beijing Continent was acquired on 30-Oct-2023.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »